

Amend claim 7 as follows:

az
sub
B1

--7) (amended) Compounds as claimed in claim 6, in which R2 is moreover selected from among the group comprising nucleoside derivatives, oligonucleotides, nucleic acids (RNA, DNA), amino acids, peptides, proteins, monosaccharides, oligosaccharides, polysaccharides, fatty acids, simple lipids, complex lipids, folic acid, tetrahydrofolic acid, phosphoric acids, inositol, vitamins, co-enzymes, flavonoids, aldehydes, halohydrins, phosphoepoxides of the formula (I) and epoxides.--

Amend claim 9 as follows:

--9) (amended) Compounds as claimed in claim 3 for the use thereof as therapeutically active substances.--

Amend claim 10 as follows:

az
sub
B1

--10) (amended) Compounds as claimed in claim 1 for the use thereof as T_γ9δ2 lymphocyte activators.--

Amend claim 11 as follows:

--11) (amended) Compounds as claimed in claim 1 for the use thereof as T_γ9δ2 lymphocyte antigens in a therapeutic composition, in particular an immunostimulant therapeutic composition or a vaccine, for primates.--

Amend claim 14 as follows:

az
sub
B1

--14) (amended) Process as claimed in claim 12, wherein the intermediate compound is reacted in a basic aqueous medium in order to convert the halohydrin functions of the intermediate compound into epoxide functions.--

Amend claim 15 as follows:

--15) (amended) Composition for extracorporeal diagnostics, wherein it comprises at least one compound as claimed in claim 3.--

Amend claim 16 as follows:

--16) (amended) Therapeutic composition, wherein it comprises at least one compound as claimed in claim 1.--

Amend claim 17 as follows:

--17) (amended) A therapeutic composition, wherein it comprises a quantity capable of being administered to a primate, in particular in contact with the peripheral bloodstream or topically, of at least one compound as claimed in claim 1.--

Amend claim 18 as follows:

--18) (amended) The composition as claimed in claim 15, wherein it moreover comprises primate T γ 9 δ 2 lymphocytes.--

Amend claim 19 as follows:

--19) (amended) The composition as claimed in claim 15, wherein it moreover comprises a proportion of interleukin suitable to bring about lymphocyte growth in the medium into which it is to be administered.--

Amend claim 20 as follows:

--20) (amended) A process for the production of a composition having the characteristic of activating T γ 9 δ 2 lymphocytes, in which at least one compound as claimed in claim 1 is used.--

Amend claim 21 as follows:

--21) (amended) A process for the production of a therapeutic composition intended for the preventive or curative treatment of a pathological condition which produces cells sensitive to T γ 9 δ 2 lymphocytes, in which process at least one compound as claimed in claim 1 is used.--

Amend claim 22 as follows:

--22) (amended) A process for the production of a therapeutic composition intended to be administered to a primate for the preventive or curative

treatment of a pathological condition which produces cells sensitive to T_γ9δ2 lymphocytes, in which process at least one compound as claimed in claim 1 is used.--

Amend claim 23 as follows:

--23) (amended) A process for the production of a therapeutic composition intended to be administered to a primate for the preventive or curative treatment of a pathological condition selected from among the group comprising cancers, infectious diseases, parasitic conditions, and pathological immunodeficiency syndromes, in which process at least one compound as claimed in claim 1 is used.--

Amend claim 24 as follows:

--24) (amended) The process according to claim claim 20, in which at least one compound as claimed in one of claims 1 to 11 is brought into contact with a medium which contains T_γ9δ2 lymphocytes, and is compatible with T lymphocyte growth, in a quantity suitable for activating these T_γ9δ2 lymphocytes in this medium.--

Amend claim 26 as follows:

--26) (amended) An extracorporeal T_γ26δ9 lymphocyte activation process, in which the T_γ9δ2 lymphocytes are brought into contact with at least one compound as claimed in claim 1 in an extracorporeal medium which contains T_γ9δ2 lymphocytes and is compatible with T lymphocyte growth.--

Amend claim 27 as follows:

--27) (amended) The process as claimed in claim 26, in which at least one compound as claimed in claim 1 is used at a concentration in the medium which brings about activation of polyclonal proliferation of T_γ9δ2 lymphocytes.--

Amend claim 28 as follows:

--28) (amended) The process as claimed in claim 26, in which a proportion of interleukin suitable to bring about lymphocyte growth in the medium is introduced into the medium.--